Company / Capital Expenditures
Xenon Pharmaceuticals Inc. Capital Expenditures History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$799.0K
FY2025
5-year range
$799.0K / $5.6M
FY2021-FY2025
Trend
-74.0%
vs FY2024
Sector context
#121 of 194
Health Care
What the data says
At $799,000, Xenon Pharmaceuticals Inc.'s capital expenditures ranks #121 of 194 in the Health Care sector. Capital Expenditures has fluctuated over the past 10 years, ranging from $279,000 in FY2016 to $6M in FY2023.
Based on SEC 10-K filings.
$799,000 in FY2025 with a 5-year CAGR of -21.2%.
Declined from $6M to $799,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -34.9%
- 5-Year CAGR
- -21.2%
- 10-Year CAGR
- -
Sector benchmark
#121 of 194 in Health CareTop 62% of 194This company $799.0K Sector average $117.5M
▼
-99.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -21.2%, indicating a declining trend.
- In FY2025, capital expenditures decreased 74.0% year-over-year.
- Ranks #121 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $799.0K | -74.0% |
| FY2024 | $3.1M | -45.3% |
| FY2023 | $5.6M | +94.1% |
| FY2022 | $2.9M | +41.2% |
| FY2021 | $2.0M | -22.3% |
| FY2020 | $2.6M | +112.7% |
| FY2019 | $1.2M | +144.6% |
| FY2018 | $507.0K | -8.0% |
| FY2017 | $551.0K | +97.5% |
| FY2016 | $279.0K | -49.4% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026